LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Kodu・Aktsiate loetelu・Erasca Inc

Erasca Inc

Suletud

3.33 2.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.27

Max

3.44

Põhinäitajad
By Trading Economics
Sissetulek	3.3M -31M
Aktsiakasum	-0.11
Kasumimarginaal	-768.16
Töötajad	103
EBITDA	8.3M -30M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+69.76% upside

Turustatistika
By TradingEconomics
Turukapital	202M 851M
Eelmine avamishind	0.87
Eelmine sulgemishind	3.33

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

1.39 / 1.44 Toetus ja vastupanu

Erasca Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. dets 2025, 23:48 UTC

Suurimad hinnamuutused turgudel

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8. dets 2025, 23:44 UTC

Market Talk

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8. dets 2025, 23:42 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8. dets 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. dets 2025, 23:13 UTC

Market Talk

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8. dets 2025, 23:09 UTC

Omandamised, ülevõtmised, äriostud

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8. dets 2025, 22:46 UTC

Market Talk

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8. dets 2025, 22:01 UTC

Market Talk

Miners Poised to Do Well in 2026 -- Market Talk

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8. dets 2025, 21:51 UTC

Market Talk

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

8. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. dets 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8. dets 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8. dets 2025, 21:36 UTC

Market Talk

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8. dets 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. dets 2025, 21:08 UTC

Market Talk

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8. dets 2025, 20:38 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8. dets 2025, 20:26 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. dets 2025, 20:18 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8. dets 2025, 20:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8. dets 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8. dets 2025, 20:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8. dets 2025, 20:05 UTC

Market Talk

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8. dets 2025, 20:01 UTC

Market Talk

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Erasca Inc Prognoos

Hinnasiht

By TipRanks

69.76% tõus

12 kuu keskmine prognoos

Keskmine 5.67 USD 69.76%

Kõrge 6 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Erasca Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Erasca Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.39 / 1.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.